This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-72 (canceled).

Claim 73 (new): A method for inhibiting expression of interleukin-5 in cells or tissues, comprising contacting cells or tissues with an antisense compound 8 to 30 nucleobases in length targeted to interleukin-5.

Claim 74 (new): The method of claim 73, wherein said antisense compound is an antisense oligonucleotide.

Claim 75 (new): The method of claim 74, wherein said antisense oligonucleotide comprises at least one chemical modification.

Claim 76 (new): The method of claim 75, wherein said modification is a sugar modification, internucleoside linkage modification or base modification.

Claim 77 (new): The method of claim 76, wherein said sugar modification is a 2'-MOE.

Claim 78 (new): The method of claim 76, wherein said internucleoside linkage is a phosphorothioate linkage.

Claim 79 (new): The method of claim 78, wherein said base modification is a 5-methyl cytidine.

Claim 80 (new): A method for reducing eosinophilia in an individual in need thereof, comprising contacting cells or tissues with an antisense compound 8 to 30 nucleobases in length targeted to interleukin-5.

Claim 81 (new): The method of claim 80, wherein said antisense compound is an antisense oligonucleotide.

Claim 82 (new): The method of claim 81, wherein said antisense oligonucleotide comprises at least one chemical modification.

Claim 83 (new): The method of claim 82, wherein said modification is a sugar modification, internucleoside linkage modification or base modification.

Claim 84 (new): The method of claim 82, wherein said sugar modification is a 2'-MOE.

Claim 85 (new): The method of claim 82, wherein said internucleoside linkage is a phosphorothioate linkage.

Claim 86 (new): The method of claim 82, wherein said base modification is a 5-methyl cytidine.

Claim 87 (new): A method for treating airway hyperresponsiveness or pulmonary inflammation in an individual in need thereof, comprising administering to said individual an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding interleukin-5 to said individual.

Claim 88 (new): The method of claim 87, wherein said antisense compound is an antisense oligonucleotide.

Claim 89 (new): The method of claim 88, wherein said antisense oligonucleotide comprises at least one chemical modification.

Claim 90 (new): The method of claim 89, wherein said modification is a sugar modification, internucleoside linkage modification or base modification.

Claim 91 (new): The method of claim 90, wherein said sugar modification is a 2'-MOE.

Claim 92 (new): The method of claim 90, wherein said internucleoside linkage is a phosphorothioate linkage.

Claim 93 (new): The method of claim 90, wherein said base modification is a 5-methyl cytidine.

Claim 94 (new): The method of claim 87, wherein said oligonucleotide is aerosolized and inhaled by said individual.

Claim 95 (new): The method of claim 87, wherein said oligonucleotide is administered intranasally, intrapulmonarily or intratracheally.

Claim 96 (new): The method of claim 87, wherein said airway hyperresponsiveness or pulmonary inflammation is associated with asthma.

Claim 97 (new): A pharmaceutical composition comprising an antisense oligonucleotide targeted to nucleic acid encoding interleukin-5 in a formulation suitable for intranasal, intrapulmonary or intratracheal administration.